Role of miR-9 in Modulating NF-κB Signaling and Cytokine Expression in COVID-19 Patients.


Journal

International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791

Informations de publication

Date de publication:
16 Aug 2024
Historique:
received: 24 06 2024
revised: 12 08 2024
accepted: 13 08 2024
medline: 31 8 2024
pubmed: 31 8 2024
entrez: 29 8 2024
Statut: epublish

Résumé

Coronavirus disease 2019 (COVID-19), caused by the SARS-CoV-2 virus, has had a significant impact on global health, with severe cases often characterized by a worsening cytokine storm. Since it has been described that the NF-κB signaling pathway, regulated by microRNAs, could play a pivotal role in the inflammatory response, in this study, the role of miR-9 in modulating NF-κB signaling and inflammatory cytokine expression in COVID-19 patients was investigated. This observational retrospective single-center study included 41 COVID-19 patients and 20 healthy controls. Serum samples were analyzed for miR-9, NF-κB, and IκBα expression levels using RT-PCR. The expression levels and production of pro-inflammatory cytokines IL-6, IL-1β, and TNF-α were measured using RT-PCR and ELISA. Statistical analyses, including correlation and regression, were conducted to explore relationships between these variables. COVID-19 patients, particularly non-survivors, exhibited significantly higher miR-9 and NF-κB levels compared to controls. A strong positive correlation was found between miR-9 and NF-κB expression (r = 0.813,

Identifiants

pubmed: 39201618
pii: ijms25168930
doi: 10.3390/ijms25168930
pii:
doi:

Substances chimiques

MicroRNAs 0
NF-kappa B 0
MIRN92 microRNA, human 0
Cytokines 0

Types de publication

Journal Article Observational Study

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : Italian Ministry of Instruction, University and Research-MIUR
ID : PRIN 2017KM79NN
Organisme : Italian Ministry of Health
ID : Ricerca Corrente

Auteurs

Carla Prezioso (C)

Department for the Promotion of Human Sciences and Quality of Life, San Raffaele University, Via di Val Cannuta 247, 00166 Rome, Italy.
Laboratory of Microbiology, IRCCS San Raffaele Roma, Via di Val Cannuta 247, 00166 Rome, Italy.

Dolores Limongi (D)

Department for the Promotion of Human Sciences and Quality of Life, San Raffaele University, Via di Val Cannuta 247, 00166 Rome, Italy.
Laboratory of Microbiology, IRCCS San Raffaele Roma, Via di Val Cannuta 247, 00166 Rome, Italy.

Paola Checconi (P)

Department for the Promotion of Human Sciences and Quality of Life, San Raffaele University, Via di Val Cannuta 247, 00166 Rome, Italy.
Laboratory of Microbiology, IRCCS San Raffaele Roma, Via di Val Cannuta 247, 00166 Rome, Italy.

Marco Ciotti (M)

Unit of Virology, Tor Vergata University Hospital, 00133 Rome, Italy.

Jacopo M Legramante (JM)

Department of Systems Medicine, University of Rome Tor Vergata, 00133 Rome, Italy.
Emergency Department, Tor Vergata University Hospital, 00133 Rome, Italy.

Carlo M Petrangeli (CM)

Emergency Department, Tor Vergata University Hospital, 00133 Rome, Italy.

Francesca Leonardis (F)

Emergency Department, Tor Vergata University Hospital, 00133 Rome, Italy.
Department of Surgical Sciences, University of Rome Tor Vergata, 00133 Rome, Italy.

Alfredo Giovannelli (A)

Unit of Laboratory Medicine, Tor Vergata University Hospital, 00133 Rome, Italy.

Alessandro Terrinoni (A)

Unit of Laboratory Medicine, Tor Vergata University Hospital, 00133 Rome, Italy.
Department of Experimental Medicine, University of Rome Tor Vergata, 00133 Rome, Italy.

Sergio Bernardini (S)

Unit of Laboratory Medicine, Tor Vergata University Hospital, 00133 Rome, Italy.
Department of Experimental Medicine, University of Rome Tor Vergata, 00133 Rome, Italy.

Marilena Minieri (M)

Unit of Laboratory Medicine, Tor Vergata University Hospital, 00133 Rome, Italy.
Department of Experimental Medicine, University of Rome Tor Vergata, 00133 Rome, Italy.

Cartesio D'Agostini (C)

Department of Experimental Medicine, University of Rome Tor Vergata, 00133 Rome, Italy.
Laboratory of Microbiology, Tor Vergata University Hospital, 00133 Rome, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH